NEW YORK, NY, May 28, 2015 – AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced the appointment of Ed Borkowski, C.P.A., M.B.A. to the Board of Directors effective May 28, 2015.

Mr. Borkowski brings a wealth of experience and credentials to AzurRx BioPharma. He currently works at Amerigene and served as the CFO for ConvaTec, CareFusion Corporation and Mylan Inc.  Earlier in his career, Mr. Borkowski held key leadership positions in the finance departments at Pharmacia and American Home Products.  He started off his career as an auditor at Arthur Andersen, holds an MBA from Rutgers and is a Certified Public Accountant.

"I am delighted to welcome Ed to the AzurRx Board” said Thijs Spoor, Chairman of AzurRx BioPharma. “This is a pivotal time for AzurRx as the company is making significant progress in advancing our two lead compounds. We believe Ed’s valuable expertise and knowledge of the financial community combined with his interest in the healthcare sector will help us achieve our objective of providing better therapies to the global gastrointestinal patient community.

"I am pleased to be working with the AzurRx team” said Mr. Borkowski, “and look forward to adding my voice and experience to help AzurRx progress in its goals of bringing transformational therapies to patients. "

About AzurRx BioPharma, Inc.
AzurRx BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infection. The company is headquartered in New York, NY, with scientific operations based in Langlade, France.

Company website address: www.azurrx.com

Forward-Looking Statements
This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Additional information concerning the Company and its business, including factors that potentially could materially affect the Company’s financial results, are contained in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more Information:      
AzurRx BioPharma, Inc.
1410 Broadway
New York NY 10018 USA
Phone: (646)-699-7855
This email address is being protected from spambots. You need JavaScript enabled to view it.